Generated by AI
Inovio Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company’s work centers on DNA-based immunotherapies and vaccines designed to help prevent or treat conditions such as recurrent respiratory papillomatosis, cervical dysplasia, and other virus-associated or oncology indications. Its platform combines synthetic DNA design with proprietary delivery technology to support immune-system activation across a range of therapeutic areas. Inovio’s current product pipeline reflects an emphasis on diseases linked to human papillomavirus as well as selected infectious and cancer-related programs. Based in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals Inc. occupies a specialized position in the biotechnology market as a developer of next-generation DNA medicine technologies.
Website660 West Germantown Pike
Plymouth Meeting, PA, 19462
United States
The latest articles about INO.
INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with RRP.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about INO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.